Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon, Robert M; Rudick, Richard A; Munschauer, Frederick E; Mass, Michele K; Salazar, Andres M; Coats, Michael E; Labutta, Robert; Richert, John R; Cohan, Stanley L; Genain, Claude; Goodkin, Donald; Toal, Martin; Riester, Katherine

Herndon, Robert M; Rudick, Richard A; Munschauer, Frederick E; Mass, Michele K; Salazar, Andres M; Coats, Michael E; Labutta, Robert; Richert, John R; Cohan, Stanley L; Genain, Claude; Goodkin, Donald; Toal, Martin; Riester, Katherine.

Affiliation

Herndon RM; University of Mississippi, VA Medical Center, Jackson, MS 39216, USA. rherndon@neurology.umsmed.edu

Mult Scler ; 11(4): 409-19, 2005 Aug.

Article in En | MEDLINE | ID: mdl-16042223

Subject(s)

Adjuvants, Immunologic/therapeutic use; Interferon-beta/therapeutic use; Multiple Sclerosis/immunology; Multiple Sclerosis/therapy; Activities of Daily Living; Adolescent; Adult; Age of Onset; Autoantibodies/blood; Female; Humans; Interferon beta-1a; Male; Middle Aged; Recurrence; Safety; Treatment Outcome; Walking

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Adjuvants, Immunologic / Interferon-beta / Multiple Sclerosis Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2005 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links